BioSynTech Malaysia Group Sdn Bhd |

29 Apr [MCE] Antibody Drug Conjugate —“Biological Missile” of Targeted Cancer Therapy

Posted at 08:10h in News by RevcorpBSTM

0 Likes

Antibody drug conjugates (ADCs) are class of targeted therapies that combine precise targeting capabilities of monoclonal antibodies with the potent effects of cytotoxic payloads. Known for their ability to selectively identify and destroy cancer cells, ADCs represent a groundbreaking advancement in oncology. Figure 1. The...

24 Apr [MCE] GJ103 and Lamin B1 Antibody: How to Conduct Chronic Kidney Disease Research?

Posted at 02:37h in News by Editorial BSTM

0 Likes

Chronic kidney disease (CKD) poses a significant global health issue, leading to the progressive loss of kidney function. Renal fibrosis commonly accompanies CKD, characterized by excessive deposition of extracellular matrix (ECM). This process causes tissue remodeling and scarring in the renal parenchyma. Myofibroblasts drive renal fibrosis through...

22 Apr [MCE] Achieve Advanced Precision with Molecular Interaction Technologies

Posted at 01:50h in News by Editorial BSTM

0 Likes

Molecular interaction analyses have become invaluable tools in modern biomedical and life science research. They enable scientists to unravel the complex biological processes, identify potential drug candidates, understand drug-target binding kinetics, and accelerate with the discovery of novel therapeutics. At MedChemExpress (MCE), we offer a...

Contact Us

Social Media

April 2025

29 Apr [MCE] Antibody Drug Conjugate —“Biological Missile” of Targeted Cancer Therapy

24 Apr [MCE] GJ103 and Lamin B1 Antibody: How to Conduct Chronic Kidney Disease Research?

22 Apr [MCE] Achieve Advanced Precision with Molecular Interaction Technologies

Site Map

Sign Up for Our Newsletter

Social Media

Contact Us

ABOUT US